Brokerages Set TriSalus Life Sciences, Inc. (NASDAQ:TLSI) Price Target at $11.79

TriSalus Life Sciences, Inc. (NASDAQ:TLSI) has received an average rating of “Buy” from the nine research firms that are covering the stock, Marketbeat reports. Seven equities research analysts have rated the stock with a buy recommendation and two have issued a strong buy recommendation on the company. The average 1 year target price among analysts that have updated their coverage on the stock in the last year is $11.79.

Several research analysts recently weighed in on TLSI shares. Northland Securities assumed coverage on TriSalus Life Sciences in a research report on Friday, October 25th. They set an “outperform” rating and a $12.50 price target on the stock. Cantor Fitzgerald initiated coverage on TriSalus Life Sciences in a report on Tuesday, December 17th. They issued an “overweight” rating and a $10.00 target price on the stock. Roth Mkm restated a “buy” rating and set a $11.00 price target on shares of TriSalus Life Sciences in a report on Friday, January 24th. Roth Capital upgraded shares of TriSalus Life Sciences to a “strong-buy” rating in a research note on Monday, November 11th. Finally, Canaccord Genuity Group decreased their target price on shares of TriSalus Life Sciences from $12.00 to $11.00 and set a “buy” rating for the company in a research note on Friday, November 15th.

TriSalus Life Sciences Stock Performance

NASDAQ TLSI opened at $5.57 on Monday. The firm’s 50 day moving average price is $4.70 and its two-hundred day moving average price is $4.74. The stock has a market cap of $169.85 million, a price-to-earnings ratio of -2.24 and a beta of 0.51. TriSalus Life Sciences has a twelve month low of $3.50 and a twelve month high of $10.42.

Insiders Place Their Bets

In related news, major shareholder Equity Ab Frankenius purchased 62,972 shares of TriSalus Life Sciences stock in a transaction on Tuesday, December 17th. The stock was bought at an average price of $3.97 per share, with a total value of $249,998.84. Following the completion of the transaction, the insider now directly owns 6,230,748 shares of the company’s stock, valued at approximately $24,736,069.56. This represents a 1.02 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO James Emmett Young acquired 6,000 shares of the stock in a transaction dated Wednesday, February 5th. The shares were bought at an average cost of $5.65 per share, for a total transaction of $33,900.00. Following the acquisition, the chief financial officer now owns 30,000 shares in the company, valued at $169,500. The trade was a 25.00 % increase in their position. The disclosure for this purchase can be found here. Insiders acquired 124,868 shares of company stock valued at $575,843 over the last ninety days. Corporate insiders own 32.80% of the company’s stock.

Institutional Investors Weigh In On TriSalus Life Sciences

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Geode Capital Management LLC grew its holdings in TriSalus Life Sciences by 45.4% during the third quarter. Geode Capital Management LLC now owns 200,427 shares of the company’s stock valued at $924,000 after purchasing an additional 62,542 shares during the last quarter. MSD Partners L.P. acquired a new position in TriSalus Life Sciences in the 3rd quarter valued at $184,000. Walleye Capital LLC bought a new position in TriSalus Life Sciences in the 3rd quarter worth $66,000. Virtu Financial LLC acquired a new position in TriSalus Life Sciences during the 3rd quarter worth $92,000. Finally, Vestcor Inc bought a new stake in TriSalus Life Sciences during the third quarter valued at about $108,000. 2.58% of the stock is currently owned by institutional investors and hedge funds.

About TriSalus Life Sciences

TriSalus Life Sciences, Inc, a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer.